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Background: The objective of this Phase I dose escalation study was to explore the safety and tolerability of
eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma
(STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy.
Methods: Patients aged 18 or older with histologically confirmed, locally advanced or metastatic STS were treated with
1 cycle of AI followed by AI with eltrombopag starting at Cycle 2, using 2 different dosing schedules. The study design
included an eltrombopag dose escalation phase starting at 75 mg daily to determine the optimal biological dose (OBD).
Results: Eighteen patients were enrolled and 15 received at least 1 dose of chemotherapy; 3 patients withdrew prior to
receiving eltrombopag. Seven, 4, and 1 patients received 75 mg, 100 mg, and 150 mg eltrombopag daily, respectively. No
dose-limiting toxicities were reported. Due to slow recruitment, the study was closed prior to identifying an OBD. The
most common hematologic adverse events (AEs) were thrombocytopenia (80%), neutropenia (73%), and anemia (67%).
The most common nonhematologic AEs were fatigue (53%), alanine aminotransferase increased, constipation, and nausea
(47% each). Eleven of 12 patients who received eltrombopag completed at least 2 chemotherapy cycles; all had increased
platelet counts on Day 1 of Cycle 2 (cycle with eltrombopag) compared to Day 1 of Cycle 1 (cycle without eltrombopag).
Conclusions: Although data are limited, safety data were consistent with the known toxicities of AI combination
chemotherapy or the side effect profile of eltrombopag seen in other studies. Available data suggest a potential pre- and
post-chemotherapy dosing scheme for eltrombopag when administered with AI chemotherapy, and support further
investigation of eltrombopag treatment in patients with chemotherapy-induced thrombocytopenia.
Keywords: Sarcoma, Platelets, Thrombopoietin receptor agonists, Chemotherapy, Myelosuppression, Chemotherapy-
induced thrombocytopeniaBackground
Thrombocytopenia is a common treatment-related
Grade 3/4 adverse event (AE) and dose-limiting toxicity
for various chemotherapy regimens [1-4]. Doxorubicin
and ifosfamide, alone and in combination (AI), are active
in the treatment of soft tissue sarcomas (STS), with
demonstrated positive response rates and improvements
in overall survival; however, both agents have been* Correspondence: conrad.a.messam@gsk.com
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reproduction in any medium, provided the orassociated with Grade 3/4 thrombocytopenia that is cu-
mulative with successive chemotherapy cycles [5-10].
Chemotherapy-induced thrombocytopenia (CIT) may
lead to dose reductions or dose delays, resulting in less
than optimal disease control. In severe cases, CIT may
result in hemorrhage and a need for platelet transfu-
sions, which have cost and safety limitations [6,8,9,11].
Although interleukin-11 (IL-11), a hematopoietic growth
factor with thrombopoietic activity, is approved for the
treatment of CIT in the US, it is not approved in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adverse effects that limit its use [12-14].
Eltrombopag, an oral, nonpeptide, thrombopoietin re-
ceptor agonist, increases platelet counts in adult patients
with chronic immune thrombocytopenia (ITP) [15-19]
and chronic liver disease due to hepatitis C virus infec-
tion [20,21].
A Phase II, multicenter, placebo-controlled study
tested 3 different doses of eltrombopag vs placebo in
patients with solid tumors receiving carboplatin and pacli-
taxel chemotherapy. The study demonstrated that
eltrombopag administration for 10 days post-chemother-
apy administration on Day 1 resulted in increased platelet
counts starting at Day 8 compared to placebo, with peak
platelet counts reached between Day 18 and Day 22 [22].
The study did not meet its primary endpoint of reducing
the platelet count change from Day 1 of Cycle 2 to the
platelet nadir of Cycle 2, compared to placebo [22].
Thrombocytopenia remains an important clinical
problem in the treatment of cancer. As such, this study
explored the safety and tolerability of eltrombopag
administered according to 2 dosing schedules in patients




The primary objective of this Phase I study was to deter-
mine the safety and tolerability of eltrombopag in
patients with locally advanced or metastatic STS recei-
ving combination chemotherapy with AI. Secondary
objectives were to determine the optimal biological dose
(OBD), pharmacokinetics (PK), and pharmacodynamics
(PD) of eltrombopag in these patients; and to evaluate
the impact of eltrombopag on the PK of doxorubicin
and doxorubicinol in this treatment setting.
The study protocol, any amendments, informed con-
sent, and other information that required pre-approval
were reviewed and approved by the sites where patients
were recruited into the study: Western Institutional
Review Board, Olympia, WA, USA; Institutional Review
Board. Pennsylvania Hospital, Philadelphia, PA, USA;
and the University of Texas, M. D. Anderson Cancer
Center, Surveillance Committee FWA-363, Houston,
TX, USA. This study was conducted in accordance with
the International Conference on Harmonisation’s Guide-
lines for Good Clinical Practice (ICH GCP) and all
applicable patient privacy requirements, and the ethical
principles that are outlined in the Declaration of
Helsinki. This study is registered at www.clinicaltrials.
gov (NCT00358540).
All participants provided informed consent prior to
performance of any study-specific procedures. All pa-
tients were scheduled to receive 10 days of eltrombopagdosing starting in Cycle 2, either continuously for 10 days
following AI chemotherapy (Days 5 to 14) or for 5 days
before (Days −5 to −1) and 5 days after (Days 5 to 9) AI
chemotherapy (Days 1 to 4). Each cycle consisted of
21 days. Doxorubicin was administered as a 75 mg/m2
intravenous (IV) bolus (Day 1) or as 3 consecutive
25 mg/m2 IV boluses (Days 1 to 3); ifosfamide was
administered as a 2.5 g/m2 IV infusion for 4 days (Days
1 to 4). Mesna and dexrazoxane were administered as
per the current standard of care.
The original study design included 2 components: a
dose-escalation phase to determine the OBD of eltrom-
bopag in combination with AI, with a daily starting dose
of 75 mg eltrombopag and escalating in a stepwise fash-
ion to 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg
daily; and an expansion phase to enroll additional
patients at the OBD to a maximum of 48 total patients,
in order to further explore the efficacy of eltrombopag
in this patient population. Due to slow recruitment, dose
escalation was halted at the 150-mg dose level prior to
identification of an OBD, the expansion phase was not
initiated, and the study was closed prior to completion.
Study completion was defined as receiving ≥ 1 dose of
eltrombopag starting from Cycle 2 and completing all
visits through to the end of Cycle 2. Patients were
permitted to stay on study for up to 6 cycles of chemo-
therapy (5 cycles of eltrombopag dosing).
Patient selection
Eligible patients were age 18 or older with histologically
confirmed, locally advanced or metastatic STS; an Eastern
Cooperative Oncology Group (ECOG)-Zubrod perform-
ance status of 0 or 1; adequate hematologic, hepatic, and
renal function; a life expectancy of ≥ 3 months; no history
of platelet disorders or dysfunction, or bleeding disorders;
and were otherwise candidates for AI chemotherapy.
Study enrollment was initially limited to chemotherapy-
naïve patients. A protocol amendment (January 2008)
during the active enrollment period allowed enrollment of
patients with 0 or 1 previous chemotherapy regimens and
required that all patients had developed ≥Grade 2
thrombocytopenia (platelet nadir ≤ 75,000/μL) in a pre-
vious chemotherapy treatment setting. Alternatively,
patients with no previous chemotherapy treatment should
have developed ≥Grade 2 thrombocytopenia during a pre-
vious AI chemotherapy cycle, with AI at the same dose
and schedule planned in the 2 cycles following enrollment
into the study. An additional change in this amendment
allowed enrollment for patients with thromboembolic
events (TEEs) > 6 months previously; prior to this amend-
ment patients with a history of TEEs were excluded from
the study. A subsequent (July 2009) protocol amendment
required that patients have adequate cardiac function at
baseline, as measured by echocardiogram (ECHO) or
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able in vitro data demonstrated that eltrombopag was an
inhibitor of breast cancer resistance protein (BCRP) efflux
transporter, for which doxorubicin and potentially its
metabolite, doxorubicinol, are substrates. As these find-
ings suggested that eltrombopag had the potential to
increase doxorubicin(ol) plasma concentrations, the pro-
tocol was amended to implement additional cardiac moni-
toring and PK sampling for doxorubicin(ol).
Patients were excluded if they had > 1 previous chemo-
therapy regimens in any disease setting; preexisting
cardiovascular disease; any known clotting disorder as-
sociated with hypercoagulability; prior treatment that
affected platelet function or anticoagulants for > 3 con-
secutive days within 2 weeks of the study start and until
the end of the study; recent history of drug-induced
thrombocytopenia; history of prior radiotherapy (RT) to
more than 20% bone marrow bearing sites; planned cata-
ract surgery; or any clinical abnormality or laboratory
parameters that interfered with study treatment or con-
ferred a risk for participation in the study.Study assessments, procedures, and analyses
Assessments performed at screening (within 14 days
prior to the first cycle of treatment) included evaluation
of eligibility criteria; medical history; routine physical
examination; ECOG performance status; risk factors for
kidney impairment and cataracts; 12-lead electrocardio-
gram (ECG); laboratory assessments (hematology with
complete blood count, serum chemistries, urinalysis, and
renal assessments); and ophthalmologic examination.
The July 2009 amendment required cardiac monitoring
using ECHO or MUGA scans at baseline and every
3 cycles.
Physical examinations were performed on study Day 1
of each cycle and on the last day of Cycle 6 or upon
withdrawal from study. Ophthalmic assessment was
performed at study completion/withdrawal and also at
the 6-month follow-up visit. Bleeding events, AE/toxicity
assessment, and concomitant medications were assessed
at each study visit and on the last day of Cycle 6 or upon
withdrawal from the study. Additional safety assess-
ments (renal assessments, ECG recordings, hematology
assessments, and chemistry assessments) were com-
pleted throughout the study at protocol-specified time
points.
Safety and efficacy analyses were summarized by de-
scriptive statistics. Safety analyses were reported using
the safety population, comprising all patients who re-
ceived ≥ 1 dose of AI chemotherapy. Efficacy analyses
were reported using the efficacy population, comprising
all patients who received ≥ 1 dose of eltrombopag and
had at least 1 platelet count measurement in each ofCycles 1 and 2. Eltrombopag PK was analyzed and will
be reported elsewhere.Results
Patient demographics and disposition
Due to slow patient recruitment over a 4-year period,
enrollment into the study was ended prior to achieving
sufficient patients to meet all predetermined study ob-
jectives, including identification of OBD and enrollment
into an expansion phase. In addition, no evaluable doxo-
rubicin PK samples were collected for assessment of the
potential doxorubicin-eltrombopag PK interaction. A
total of 18 patients were enrolled into the study. Three
patients withdrew prior to receiving any chemotherapy
and 15 patients received at least 1 dose of chemotherapy
(safety population, Table 1). Of these 15 patients, 12 re-
ceived at least 1 dose of eltrombopag: 7, 4, and 1 pa-
tients received 75 mg, 100 mg, and 150 mg eltrombopag
daily, respectively (Figure 1). Two of the 7 patients who
received 75 mg eltrombopag were treated for 10 days
post AI chemotherapy; the remainder of patients re-
ceived eltrombopag for 5 days prior to and 5 days post
AI chemotherapy. Three patients within the safety popu-
lation withdrew prior to eltrombopag dosing: 1 due to a
serious AE (SAE, Grade 3 pulmonary embolism), 1 due
to disease progression, and 1 due to patient decision.
The median age (range) was 44 (20–65) years and 53%
were male.
During Cycle 2, 12 patients received a median (range)
of 8.5 (2–17) days of treatment with eltrombopag; 7
(2–17), 8.5 (6–10), and 10.0 days for the 75-mg, 100-mg,
and 150-mg dose groups, respectively. During Cycle 3, 9
patients received a median (range) of 10 (3–12) days of
treatment with eltrombopag; 10.0 (3–12), 10.0 (7–10),
and 10.0 days for the eltrombopag 75 mg, 100-mg, and
150-mg dose groups, respectively. During Cycle 4, 5
patients received a median (range) of 10 (3–10) days of
treatment with eltrombopag; 10.0 (3–10) and 10.0 days
for the eltrombopag 75 mg and 100 mg dose groups,
respectively. During Cycle 5, 2 patients received a
median (range) of 6 (2–10) days of treatment with eltrom-
bopag; 2 and 10.0 days for the eltrombopag 75-mg and
100-mg dose groups, respectively.Safety
Since the study did not complete as planned, analyses of
safety are limited. Five patients who received eltrom-
bopag completed the study (ie, received at least 1 dose
of eltrombopag and underwent all visits through to com-
pletion of Cycle 2). The majority of patients in the safety
population (10/15, 67%) withdrew prior to study com-
pletion. Reasons for study withdrawal included AEs; loss
to follow-up; disease progression; patient decision; poor
Table 1 Patient demographics and baseline clinical characteristics (safety population)
Demographics No Eltrombopag Eltrombopag Eltrombopag Total
Eltrombopag 75 mg 100 mg 150 mg (N = 15)
(n = 3)a (n = 7) (n = 4) (n = 1)
Median age, y (range) 56.0 (20–65) 48.0 (38–62) 30.5 (23–44) 59.0 44.0 (20–65)
Gender, n (%)
Female 1 (33) 4 (57) 2 (50) 1 (100) 8 (53)
Male 2 (67) 3 (43) 2 (50) 0 (0) 7 (47)
Race, n (%)
Hispanic or Latino 1 (33) 0 (0) 2 (50) 0 (0) 3 (20)
Not Hispanic or Latino 2 (67) 7 (100) 2 (50) 1 (100) 12 (80)
Baseline clinical characteristics
Median baseline platelet count, 1000/μL (range) 256.0 300.0 264.0 388.0 281.0
(218–371) (197–368) (180–595) (180–595)
ECOG PS
ECOG 0, n (%) 0 (0) 6 (86) 0 (0) 1 (100) 7 (47)
ECOG 1, n (%) 3 (100) 1 (14) 4 (100) 0 (0) 8 (53)
aPatients were withdrawn prior to receiving eltrombopag during the second cycle.
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
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amputation; and inability to continue AI therapy.
All patients experienced at least 1 AE while enrolled
in the study. Thrombocytopenia (12 patients, 80%),
neutropenia (11 patients, 73%), and anemia (10 patients,
67%) were the most common hematologic AEs; and
fatigue (8 patients, 53%), alanine aminotransferase (ALT)
increased, constipation, and nausea (7 patients each, 47%)
were the most common nonhematologic AEs (Table 2).
Grade 3 and 4 toxicities occurring in each group are listed
in Table 3.
No AEs considered related to study treatment were
reported for patients receiving 100 mg and 150 mg dosa-
ges of eltrombopag. Five patients in the 75-mg group








Figure 1 Summary of Patient Disposition. Of 18 patients enrolled, 3 wit
chemotherapy dose (safety population). Of these 15 patients, 3 withdrew b
and 1 patients received at least 1 dose of 75 mg, 100 mg, and 150 mg eltrEltrombopag-related AEs occurring in ≥ 2 patients were
thrombocytosis (3 patients), anemia, fatigue, and throm-
bocytopenia (2 patients each).
Overall, 11 SAEs were reported in 7 patients. The 2
patients who withdrew prior to receiving any eltrombopag
experienced 3 SAEs. Four patients in the 75-mg group
experienced 7 SAEs, 1 of which (subclavian venous
thrombosis) was reported as related to eltrombopag dos-
ing. One patient in the 100-mg group experienced 1 SAE
(sepsis), which was reported as unrelated to eltrombopag.
No SAEs were reported for the 1 patient who received
150 mg eltrombopag. No deaths were reported in this
study.
Three patients reported 1 SAE each leading to








hdrew before receiving any chemotherapy and 15 received at least 1
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Table 2 Adverse events of any grade (≥ 15% of patients, safety population)
Treatment-emergent No Eltrombopag Eltrombopag Eltrombopag Total
Eltrombopag 75 mg 100 mg 150 mg (N = 15)
(n = 3)a (n = 7) (n = 4) (n = 1)
Hematologic AEs, n (%)
Thrombocytopenia 2 (67) 5 (71) 4 (100) 1 (100) 12 (80)
Neutropenia 2 (67) 5 (71) 4 (100) 0 11 (73)
Anemia 1 (33) 6 (86) 3 (75) 0 10 (67)
Leukopenia 0 3 (43) 2 (50) 0 5 (33)
Febrile neutropenia 0 2 (29) 1 (25) 1 (100) 4 (27)
Thrombocytosis 0 4 (57) 0 0 4 (27)
Nonhematologic AEs, n (%)
Fatigue 0 6 (86) 2 (50) 0 8 (53)
ALT increased 0 5 (71) 2 (50) 0 7 (47)
Constipation 0 6 (86) 1 (25) 0 7 (47)
Nausea 1 (33) 5 (71) 1 (25) 0 7 (47)
Alopecia 0 5 (71) 1 (25) 0 6 (40)
Pyrexia 1 (33) 3 (43) 2 (50) 0 6 (40)
Vomiting 1 (33) 3 (43) 2 (50) 0 6 (40)
AST increased 0 3 (43) 2 (50) 0 5 (33)
Hypokalemia 0 3 (43) 2 (50) 0 5 (33)
Confusional state 1 (33) 2 (29) 0 0 3 (20)
Hemorrhoids 0 3 (43) 0 0 3 (20)
Hypocalcemia 0 1 (14) 2 (50) 0 3 (20)
Headache 0 3 (43) 0 0 3 (20)
Edema peripheral 1 (33) 1 (14) 1 (25) 0 3 (20)
Proteinuria 0 3 (43) 0 0 3 (20)
Vitamin B12 increased 0 3 (43) 0 0 3 (20)
aPatients were withdrawn prior to receiving eltrombopag during the second cycle.
AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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eltrombopag. One of these SAEs, the Grade 3 subclavian
venous thrombosis described above, occurred in a patient
in the 75-mg group with no prior history of TEEs; further
details are included below.
Ten patients reached a platelet count > 400,000/μL on
at least 1 occasion, requiring temporary interruption of
eltrombopag per protocol; none of these platelet count
increases were associated with sequelae. Platelet count
increases occurred at various points throughout the
cycle; no pattern was observed.
Three patients in the 75-mg group reported 6 bleeding
AEs, all Grade 1. The 1 patient who received 150 mg
eltrombopag experienced Grade 3 epistaxis (Cycle 3; prox-
imal platelets 15,000/μL). No bleeding events led to dis-
continuation of eltrombopag dosing or study withdrawal,
and none were considered by the investigator to be related
to eltrombopag dosing. An additional patient who did notreceive eltrombopag reported three Grade 2 bleeding
AEs during Cycle 1 of AI chemotherapy: hematemesis
(proximal platelets 371,000/μL), hematuria (proximal
platelets 126,000/μL), and hemoptysis (proximal platelets
126,000/μL).
Two patients who received 75 mg eltrombopag and 1
patient who never received eltrombopag experienced
TEEs during the study. One patient who did not receive
eltrombopag experienced a Grade 3 pulmonary embo-
lism 3 days after completion of the first cycle of chemo-
therapy; proximal platelet counts were 126,000/μL. The
event resolved 18 days later. The 2 patients who received
75 mg eltrombopag both experienced a Grade 3 sub-
clavian venous thrombosis at proximal platelet counts of
193,000/μL and 284,000/μL. The former event, as des-
cribed above, was considered by the investigator to be
possibly related to eltrombopag dosing. The investigator
also considered that the event may have been due to a
Table 3 Grade 3 or 4 adverse events (safety population)
Treatment-emergent No Eltrombopag Eltrombopag Eltrombopag
Eltrombopag 75 mg 100 mg 150 mg
(n = 3)a (n = 7) (n = 4) (n = 1)
Hematologic AEs, n (%)
Thrombocytopenia 0 3 (43) 2 (50) 1 (100)
Neutropenia 2 (67) 4 (57) 4 (100) 0
Anemia 0 3 (43) 2 (50) 0
Leukopenia 0 3 (43) 0 0
Febrile neutropenia 0 2 (29) 0 0
Nonhematologic AEs, n (%)
Pulmonary embolism 1 (33) 0 0 0
Abdominal abscess 1 (33) 0 0 0
Abdominal pain 0 1 (14) 0 0
Mucosal inflammation 0 1 (14) 0 0
Dehydration 0 1 (14) 0 0
Subclavian vein thrombosis 0 1 (14) 0 0
Sepsis 0 0 1 (25) 0
aPatients were withdrawn prior to receiving eltrombopag during the second cycle.
AE, adverse events.
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event. The TEE resolved 6 months later. The latter patient
had concurrent estrogen use and a prior history of a TEE
(deep vein thrombosis [DVT]); the patient had been en-
rolled under a prior protocol amendment that excluded
patients with prior TEEs. The patient was withdrawn from
the study after 2 days of eltrombopag dosing and the TEE
resolved 11 days later. This event was considered by the
investigator to be unrelated to eltrombopag.
All hepatobiliary laboratory abnormalities (HBLAs)
were Grade 1 or Grade 2, none were considered related
to eltrombopag dosing, and none required permanent
discontinuation of eltrombopag or study withdrawal.
No patient experienced renal events with onset during
eltrombopag dosing or within 6 months post-treatment.
All creatinine values were reported as normal at all
assessments.
Four cardiac-related AEs (palpitations, 2 events; tachy-
cardia, 2 events) were reported for 3 patients who received
75 mg of eltrombopag. All were Grade 1 in severity and
all were considered unrelated to eltrombopag dosing. All
but one event (tachycardia) resolved. No clinically signifi-
cant ECG results were observed. All QTc values were
≤ 500 msec throughout the study. No clinically meaningful
decrease in ejection fraction was reported for the 1 patient
(in the 150-mg group) who completed MUGA/ECHO
assessment.
No new cataracts or progression of existing cataracts
was reported.Efficacy
Since the study did not complete as planned due to poor
enrollment, analyses of efficacy are also necessarily limited.
Of the 12 patients who received at least 1 dose of
eltrombopag 75 mg, 100 mg, or 150 mg, 11 patients had at
least 1 platelet count measurement in each of Cycles 1 and
2 while on study and were evaluable for efficacy. Available
data demonstrated increased pre-chemotherapy platelet
counts on Day 1 of Cycle 2 (cycle with eltrombopag) com-
pared to Day 1 of Cycle 1 (cycle without eltrombopag) in
all 11 of these patients (Figure 2). Ten of these 11 patients
received additional cycles of therapy (including eltrom-
bopag) beyond Cycle 2; of these 10, 6 showed increased
pre-chemotherapy platelet counts in all treatment cycles
compared to Cycle 1 (5 in the 75-mg group and 1 in the
100-mg group). Two patients who were chemotherapy
naïve (patients 1 and 2), and who did not have throm-
bocytopenia prior to study entry (ie, prior to the protocol
change), had higher platelet counts on Day 1 of Cycle 2
than during Cycle 1. This is most likely due to natural re-
bound or recovery of hematopoiesis at the end of Cycle 1.
Platelet nadirs for these 11 patients are shown in
Figure 3. Two of 4 patients who received 100 mg
eltrombopag daily demonstrated improved platelet
nadirs in Cycle 2 (cycle with eltrombopag) compared to
Cycle 1 (cycle without eltrombopag). The other 2
patients who received 100 mg eltrombopag daily did not
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Figure 2 Day 1 Pre-Chemotherapy Platelet Counts for Cycle 1 and Cycle 2 for Individual Patients Who Received Eltrombopag and
Completed at Least 2 Cycles (n = 11). Patients indicated with an asterisk (*) received eltrombopag for 10 days post-chemotherapy beginning in
Cycle 2; all other patients received eltrombopag beginning in Cycle 2 for 5 days pre- and 5 days post-chemotherapy.
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Thrombocytopenia is a common side effect of chemother-
apy, and multiple studies have suggested that CIT is a dose-
limiting AE in the treatment of cancer, and can necessitate
dose delays and/or dose reductions [23,24]. For example, a
database analysis of 47,159 patients with both solid tumors
and hematologic malignancies showed that TCP increased
from 11% at baseline to 22-64% following chemotherapy
treatment [24]. Grade 3/4 TCP has been reported in 63% of

































Figure 3 Platelet Nadirs in Cycle 1 and Cycle 2 of Treatment for Indiv
Least 2 Cycles (n = 11). Patients indicated with an asterisk (*) received eltr
other patients received eltrombopag beginning in Cycle 2 for 5 days pre- a[6]. An effective agent for the treatment of CIT may allow
chemotherapy administration according to schedule and
without dose delays and/or reductions.
This study evaluated the safety and efficacy of
eltrombopag in patients with advanced STS and CIT
due to receiving AI chemotherapy. Enrollment into this
study was challenging as the target study population
dwindled due to the emergence of novel standards of
care for advanced STS during the 4-year course of the
study. Despite implementation of several strategies to100 mg 150 mg
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and the study closed prior to recruitment of the planned
number of patients.
Although data are limited, repeated treatment cycles
of eltrombopag appeared to be generally well tolerated
and the safety profile was consistent with the known
safety profile of eltrombopag and with what is expected
for patients with advanced STS receiving treatment with
the AI chemotherapy regimen. TEEs were observed in
this study in 1 patient who did not receive eltrombopag
and 2 patients who received eltrombopag, consistent
with the known propensity for TEEs in cancer patients.
Both eltrombopag-treated patients had known risk
factors for TEEs (a port insertion on the same side for
one patient, and prior DVT with concurrent estrogen
for the other). Renal and cardiac events were examined
thoroughly and no eltrombopag-related renal or cardiac
events of concern were reported. After this study was
initiated, in vitro data showed eltrombopag was an
inhibitor of the BCRP-mediated transport of cimetidine.
Extensive cardiac safety assessments were subsequently
implemented through a study amendment. More recent
in vitro studies have shown the BCRP-mediated transport
of doxorubicin is not inhibited by eltrombopag at concen-
trations up to 30 μM, the highest concentration that can be
tested in vitro (unpublished data). This concentration is 3-
to 4-fold higher than the Day 1 plasma eltrombopag con-
centration after administration of 100 mg eltrombopag on
Days −5 to −1 (unpublished data). These observations sug-
gest that the risk of a clinical eltrombopag-doxorubi-
cin interaction may be far less than originally
anticipated.
As shown in Table 2, 100% of patients treated at the
100 mg and 150 mg doses experienced TCP of any
grade, whereas only in 71% of patients treated at the
75 mg experienced TCP. The main reason for this differ-
ence was that the protocol had no requirement for
patients to have thrombocytopenia for study entry when
patients were enrolling at the 75-mg dose level, and the
patients enrolled at this eltrombopag dose were also
chemotherapy naïve. The protocol was amended for
patients enrolled at the 100-mg and 150-mg dose levels
to require that the patient experience at least Grade 2
thrombocytopenia (platelets < 75,000/μL) prior to study
entry. This resulted in patients who had previously re-
ceived chemotherapy having a greater degree of throm-
bocytopenia at study entry, and explains the increased
rate of TCP observed at the higher doses.
Although there was insufficient enrollment for identifi-
cation of an OBD, no dose-limiting toxicities were ob-
served that limited eltrombopag dose escalation to
150 mg daily in the study. The 75 mg eltrombopag dose
demonstrated increased platelet counts at Day 1 of Cycle
2; however, this dose may be inadequate since it did notalso improve platelet nadirs. Determination of the OBD
for eltrombopag for patients with CIT requires further
study.
Limited data were available to explore the efficacy of
eltrombopag in this patient population. The study proto-
col required temporary interruption of eltrombopag dos-
ing when a patient’s platelet counts were > 400,000/μL.
Ten patients had platelet counts > 400,000/μL on at least
one occasion, requiring temporary eltrombopag inter-
ruption; this may have decreased efficacy for these
patients. Available platelet data showed that all patients
receiving eltrombopag demonstrated increased pre-
chemotherapy platelet counts during Cycle 2 (eltrom-
bopag dosing cycle) compared to Cycle 1 (cycle prior to
eltrombopag dosing); additionally, 6 of 10 patients who
received > 2 cycles of therapy showed increased pre-
chemotherapy platelet counts in each cycle compared to
Cycle 1. Finally, 2 of 4 patients receiving 100 mg eltrom-
bopag had improved platelet nadirs in Cycle 2 compared
to Cycle 1. Both of these patients received eltrombopag
5 days pre- and 5 days post-chemotherapy, suggesting
that this schedule might improve platelet nadirs as well
as pre-chemotherapy platelet count, allowing patients to
complete subsequent chemotherapy cycles at the planned
dose and schedule.
Further studies are needed to better assess the effects
of this pre- and post-chemotherapy schedule of eltrom-
bopag administration in combination with other chemo-
therapy regimens. In an ongoing, randomized Phase I/II
study of eltrombopag versus placebo in patients with solid
tumors receiving gemcitabine alone or in combination
with cisplatin or carboplatin (NCT01147809), eltrombopag
100 mg daily is being administered according to a pre- and
post-chemotherapy schedule (5 days before and 5 days
following Day 1 of chemotherapy). The results of this study
will further clarify the safety and efficacy of this eltrom-
bopag dosing schedule in combination with chemotherapy.Conclusions
Although data are limited, the safety profile was consistent
with the known safety profile of eltrombopag and the AI
chemotherapy regimen. These preliminary data suggest a
potential pre- and post-chemotherapy dosing scheme for
eltrombopag when administered with AI chemotherapy,
and support further investigation of eltrombopag treat-
ment in patients with CIT.Competing interests
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